Phlow promotes chief biz officer to president

Dan Hackman joined Richmond pharma company in 2020

Published February 2, 2023 by Katherine Schulte

Richmond-based Phlow Corp. has promoted Dan Hackman from chief business officer to president, the pharmaceutical manufacturing company announced Thursday.

Hackman joined Phlow in 2020. He previously worked with Kaleo Inc. as general manager of its Auvi-Q product — an injectable pen developed for emergency allergy treatment — and served as its vice president of patient access and affordability strategy from 2017 to 2020, after working as the company’s chief commercial officer from 2015 to 2017, according to his LinkedIn profile.

“I’m excited to begin this new role at Phlow and look forward to working with our best-in-class teams to secure our nation’s essential medicine supply chain and serve our commercial customers,” he said in a statement.

Hackman has a bachelor’s degree in business administration from Illinois State University and a law degree from Indiana University. His background includes executive roles at other health-related companies, including Sorin Group (now LivaNova), where from 2009 to 2015 he served as senior vice president of U.S. cardiac rhythm management and then senior vice president of strategic growth initiatives. He has also served in a variety of leadership positions at Boston Scientific Corp. as well as its subsidiary Guidant Corp.

Phlow on Thursday also announced the addition of Melinda Hancock, executive vice president and chief administrative officer of Sentara Healthcare, to its board of directors, as well as the formation of a Phlow business advisory board.

The advisory board members are:

• Salvatore Guccione, managing director, Vasto Advisors LLC
• Steven Klosk, former CEO, Cambrex Corp.
• Tim M. Mayleben, president, Exipaidia LLC
• Dr. Joe Smith, chief scientific officer, BD
• Guy Villax, former CEO and current nonexecutive board member, Hovione
• Joseph Warchol, chief financial officer for North America, Curium Pharma

In May 2020, Phlow received a $354 million, four-year federal contract from the U.S. Biomedical Advanced Research and Development Authority to create an American supply chain for generic medicines and pharmaceutical ingredients that are now made mostly in China and India that are needed to treat coronavirus.

In Petersburg, Phlow is partnering with nonprofit generic drug-maker Civica Rx and California-based AMPAC Fine Chemicals to produce COVID drugs as part of a federal initiative to create the domestic supply chain for critical pharmaceuticals and ingredients.

    Subscribe to Virginia Business.   Get our daily e-newsletter.